|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 11/02/15 Amgen Inc 10-Q 9/30/15 76:10M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 782K
2: EX-10.4 Form of Global Rsu Agreement HTML 204K
3: EX-10.6 Form of Performance Unit Agreement HTML 184K
4: EX-31 Rule 13A-14(A) Certifications HTML 37K
5: EX-32 Section 1350 Certifications HTML 26K
52: R1 Document and Entity Information HTML 40K
41: R2 Condensed Consolidated Statements of Income HTML 83K
(Unaudited)
50: R3 Condensed Consolidated Statements of Comprehensive HTML 49K
Income (Unaudited)
54: R4 Condensed Consolidated Balance Sheets (Unaudited) HTML 95K
70: R5 Condensed Consolidated Balance Sheets (Unaudited) HTML 30K
(Parenthetical)
43: R6 Condensed Consolidated Statements of Cash Flows HTML 119K
(Unaudited)
49: R7 Summary of significant accounting policies HTML 33K
37: R8 Restructuring HTML 89K
28: R9 Income taxes HTML 33K
71: R10 Earnings per share HTML 56K
56: R11 Collaborative arrangements HTML 40K
55: R12 Available-for-sale investments HTML 221K
61: R13 Inventories HTML 32K
62: R14 Goodwill and other intangible assets HTML 87K
59: R15 Financing arrangements HTML 77K
63: R16 Stockholders' equity HTML 164K
51: R17 Fair value measurement HTML 220K
53: R18 Derivative instruments HTML 172K
58: R19 Contingencies and commitments HTML 41K
76: R20 Subsequent event HTML 24K
66: R21 Summary of significant accounting policies HTML 47K
(Policies)
46: R22 Restructuring (Tables) HTML 88K
57: R23 Earnings per share (Tables) HTML 53K
48: R24 Available-for-sale investments (Tables) HTML 221K
21: R25 Inventories (Tables) HTML 31K
67: R26 Goodwill and other intangible assets (Tables) HTML 77K
73: R27 Financing arrangements (Tables) HTML 78K
32: R28 Stockholders' equity (Tables) HTML 158K
31: R29 Fair value measurement (Tables) HTML 199K
35: R30 Derivative instruments (Tables) HTML 153K
36: R31 Summary of significant accounting policies HTML 26K
(Details)
38: R32 Restructuring (Details Textual) HTML 42K
18: R33 Restructuring (Summary of Charges by Type) HTML 48K
(Details)
64: R34 Restructuring (Summary of Expenses and Payments) HTML 36K
(Details)
45: R35 Income taxes (Details) HTML 37K
47: R36 Earnings per share (Details) HTML 46K
24: R37 Collaborative arrangements (Details) HTML 47K
75: R38 Available-for-sale investments (Details) HTML 73K
12: R39 Available-for-sale investments (Fair Values by HTML 38K
Classification) (Details)
39: R40 Available-for-sale investments (Fair Values by HTML 44K
Contractual Maturity) (Details)
69: R41 Available-for-sale investments (Unrealized Losses HTML 65K
and Fair Values) (Details)
23: R42 Available-for-sale investments (Details Textual) HTML 32K
30: R43 Inventories (Details) HTML 34K
34: R44 Goodwill and other intangible assets (Goodwill HTML 30K
Roll Forward) (Details)
42: R45 Goodwill and other intangible assets (Idenfitiable HTML 53K
Intangible Assets) (Details)
17: R46 Goodwill and other intangible assets (Details HTML 49K
Textual)
27: R47 Financing arrangements (Details) HTML 150K
14: R48 Stockholders' equity (Details Textual) HTML 35K
68: R49 Stockholders' equity (Share Repurchase Program) HTML 29K
(Details)
22: R50 Stockholders' equity (Components of AOCI) HTML 83K
(Details)
65: R51 Stockholders' equity (Relcassifications out of HTML 50K
AOCI) (Details)
25: R52 Fair value measurement (Details) HTML 167K
40: R53 Fair value measurement (Changes in Contingent HTML 32K
Consideration Obligation) (Details)
13: R54 Fair value measurements (Details Textual) HTML 60K
16: R55 Derivative instruments (Cross-currency Swaps) HTML 43K
(Details)
33: R56 Derivative instruments (Effective Potion of HTML 30K
Unrealized Gain (Loss)) (Details)
19: R57 Derivative instruments (Locations and Effective HTML 47K
Potions of Gain (Loss) Reclassified out of AOCI)
(Details)
72: R58 Derivative instruments (Locations and Gain (Loss) HTML 28K
for Derivatives Not Designated as Hedging
Instruments) (Details)
44: R59 Derivative instruments (Details) HTML 54K
60: R60 Derivative instruments (Details Textual) HTML 74K
26: R61 Contingencies and commitments (Details) HTML 25K
29: R62 Subsequent event (Details) HTML 28K
74: XML IDEA XML File -- Filing Summary XML 139K
15: EXCEL IDEA Workbook of Financial Reports XLSX 86K
6: EX-101.INS XBRL Instance -- amgn-20150930 XML 3.62M
8: EX-101.CAL XBRL Calculations -- amgn-20150930_cal XML 217K
9: EX-101.DEF XBRL Definitions -- amgn-20150930_def XML 628K
10: EX-101.LAB XBRL Labels -- amgn-20150930_lab XML 1.59M
11: EX-101.PRE XBRL Presentations -- amgn-20150930_pre XML 914K
7: EX-101.SCH XBRL Schema -- amgn-20150930 XSD 181K
20: ZIP XBRL Zipped Folder -- 0000318154-15-000025-xbrl Zip 262K
| Exhibit |
1. | I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.; |
2. | Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and |
(d) | Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting. |
Date: November 2, 2015 | |
Chairman of the Board, | |
Chief
Executive Officer and President | |
1. | I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.; |
2. | Based
on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
4. | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and |
(d) | Disclosed in this quarterly report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting. |
Date: November 2, 2015 | /s/ DAVID W. MELINE |
Executive Vice President and Chief Financial Officer | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/2/15 | None on these Dates | ||
| For Period end: | 9/30/15 | |||
| List all Filings | ||||